Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Oldfield Partners Overstone World All Cap Equity Fund Richard Oldfield | “Sanofi was a detractor this quarter. A run of disappointing late-stage trial readouts has revived the question that hangs over the company: whether Sanofi can establish enough new products to offset the Dupixent (its blockbuster immunology drug) patent cliff in 2031. We made the investment believing the market was already too gloomy about the Dupixent cliff, and we were early. We underestimated how much of the late-stage pipeline would disappoint. Those failures contributed to the departure of chief executive Paul Hudson after six years. Belén Garijo, formerly CEO of Merck KGaA, took over in April with an explicit focus on improving R&D. She has moved quickly: in June the company named Paulo Fontoura, a long-serving Roche employee, as head of pharma R&D from September, replacing Houman Ashrafian after barely three years. We are wary of reading too much into the management changes, and the market met both appointments with scepticism. But a board willing to hold management to account for the pipeline, with a chief executive focused on fixing the problems, is not the worst backdrop for an investment priced for disappointment. Against this backdrop the business has done well. First-quarter sales and earnings both rose 14%. This is now a focused pharmaceutical business following the separation of consumer health, generating substantial free cash flow, with a conservative balance sheet and returning capital through ongoing buybacks and dividends. Today's valuation effectively writes off the pipeline: the market prices Sanofi's ex-Dupixent business for gentle decline and credits the rest almost nothing. We think that is too pessimistic. The existing portfolio of drugs provides a solid floor, and merely stabilising profits beyond the cliff would, on our estimates, justify a valuation around 20% higher than today's. Anything the pipeline delivers is additional upside. A dividend yield of about 4.5% pays us to wait.” | NEUTRAL | Q2 2026 Jul 8, 2026 | View Pitch |
Oldfield Partners Overstone Global Large Cap Portfolio Manager | “Sanofi was a detractor this quarter. A run of disappointing late-stage trial readouts has revived the question that hangs over the company: whether Sanofi can establish enough new products to offset t” | BULL | Q2 2026 Jun 30, 2026 | View Pitch |
Oakmark Global Select Fund David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. Sitarz | “Sanofi's strong fundamentals and core asset Dupixent are undervalued due to temporary vaccine market volatility and patent cliff anxieties. The manager bought shares to capitalize on this valuation gap, expecting the R&D pipeline to normalize vaccine performance and unlock long-term growth.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Ariel International Fund Ariel Investments, LLC | “Market concerns over a potential vaccine critic heading the US HHS caused an industry-wide sell-off, which the manager believes is an overreaction for Sanofi given its vaccine division's small revenue share. The pipeline for immunology and key products like Dupixent remain underappreciated at current prices.” | BULL | Q4 2024 Dec 31, 2024 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
